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Abstract
Retinoids are vitamin A metabolites best known for their role in embryonic 
development. Indeed, retinoid acid (RA) signaling plays a key role in regulating the 
development of the embryo body-plan by controlling embryonic stem cells (SCs). 
Retinoids function through their ability to induce cellular differentiation. Mutations 
in RA signaling pathway genes occur in most human cancers. The classic example is 
the chromosomal translocation involving RA receptor alpha in acute promyelocytic 
leukemia (APL). Because all-trans retinoic acid (ATRA) is a highly effective and often 
curative treatment for APL patients, determining if retinoids are efficacious for other 
cancer types is imperative. We review the current research on retinoids in colorectal 
cancer (CRC) and provide bioinformatics analyses of RA signaling. Our results show 
that most RA pathway genes are overexpressed and often mutated in CRC. Moreover, 
aberrant expression of many RA signaling proteins predicts decreased CRC patient 
survival. We also review aldehyde dehydrogenase (ALDH) expression in CRC 
because ALDH is a key enzyme in RA signaling, which regulates colonic SCs. Further 
investigation of RA signaling mechanisms that regulate colon SCs and how dysregu-
lation contributes to the SC overpopulation that drives CRC growth should provide 
insight into strategies for designing new SC-targeted therapies for CRC.
Keywords: retinoic acid, stem cells, colon cancer, adenomatous polyposis coli, 
aldehyde dehydrogenase
1. Introduction
Our goal herein is to review current research findings on retinoids in colorectal 
cancer (CRC), and to provide an update from our bioinformatics analysis of RA 
signaling components in CRC. Retinoic acid (RA) is currently being used in the 
treatment of specific types of human cancers [1]. The classic example is use of 
ATRA as first line treatment for acute promyelocytic leukemia (APL). RA therapy 
has also been shown to improve survival in patients with neuroblastoma [2–4]. 
Additionally, RA-based agents have been evaluated for clinical anti-cancer activity 
in breast cancer and in lung cancer [5]. In this review, we discuss the anti-cancer 
activity of retinoids using in vitro and in vivo models of CRC, and the use of ATRA 
as a differentiation agent in SC research [4, 6–8].
A strong rationale to investigate RA signaling in oncology research is that ATRA 
is an effective drug used to treat APL patients. Indeed, ATRA effectively induces 
APL cells to terminally differentiate into neutrophils [9–11]. Current treatment regi-
mens for APL also include arsenic in combination with ATRA because the combina-
tion provides a synergic drug response that cures the majority of APL patients, who 
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would otherwise be facing a highly fatal illness. The precise mechanism involved in 
triggering APL cells have been extensively studied with the hope of understanding 
how it can be applied to trigger differentiation in other cancer types. What appears 
to be the basis for clinical success in treating APL is that the RA/arsenic combina-
tion not only induces terminal differentiation, but it also abrogates self-renewal of 
APL SCs [12]. Thus, future retinoid-based treatments for other cancers will likely 
necessitate drug combinations that incorporate a RA signaling differentiation 
therapy and a SC-targeting therapy that inhibits cancer SC self-renewal.
2. Key components of the retinoic acid signaling pathway
To understand how the RA signaling pathway is altered in cancer and to provide a 
basis for designing retinoid-based treatment approaches to cancer, we provide a brief 
description of the key components in the RA signaling pathway. The reader is referred 
to Das et al. [13] for more detailed information. Listed below are the main proteins 
essential to proper functioning of the RA signaling pathway. A simplified schematic 
of the RA signaling pathway is illustrated in Figure 1.
2.1 STRA6 (stimulated by retinoic acid 6)
STRA6 is a cell surface protein that functions as a receptor to accept all-trans 
retinol from the extracellular retinol-binding protein RBP4 and to transport retinol 
across the cell membrane. STRA6 removes the retinol from RBP4 and transfers it to 
RBP1 in the cytoplasm. STRA6 does not transport RA.
2.2 LRAT (lecithin retinol acyltransferase)
LRAT is an enzyme that converts retinol to all-trans retinyl esters, which is 
a storage form of vitamin A. LRAT also functions to enhance cellular uptake of 
retinol by STRA6, which contributes to the activation of the RA signaling cascade.
2.3 RDHs (retinol dehydrogenases)
RDHs are a family of dehydrogenase enzymes involved in the conversion of 
retinol to retinaldehyde by catalyzing the oxidation of cis-isomers of retinol, 
including 11-cis-, 9-cis-, and 13-cis-retinol in an NAD-dependent manner. This 
family of short-chain dehydrogenases/reductases functions to catalyze the final 
step in the biosynthesis of 11-cis retinaldehyde.
2.4 DHRS3 (retinaldehyde reductase-3)
DHRS3 is an oxidoreductase that catalyzes the oxidation/reduction of all-
trans-retinal to all-trans-retinol in the presence of NADPH. DHRS3 is essential for 
preventing the formation of excess RA during embryonic development.
2.5 ADHs (alcohol dehydrogenases)
ADHs are a family of alcohol dehydrogenases involved in retinoid metabolism 
via conversion of retinol to retinaldehyde by catalyzing the NAD-dependent 
oxidation of all-trans-retinol and its derivatives such as all-trans-4-hydroxyretinol. 
These enzymes metabolize a wide variety of substrates, including ethanol, retinol, 
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aliphatic alcohols, hydroxysteroids, and products of lipid peroxidation. ADHs 
consist of several homo- and heterodimers of alpha, beta, and gamma subunits, 
which plays major roles in ethanol catabolism. For example, three genes encoding 
alpha, beta, and gamma subunits of ADH1 are tandemly organized in a genomic 
segment as a gene cluster.
2.6 RBPs (retinol-binding proteins)
RBP1 (Retinol Binding Protein 1) and RBP2 (Retinol Binding Protein 2) are 
cytoplasmic retinol-binding proteins, which contribute to retinol uptake, storage, 
Figure 1. 
This figure illustrates a simplified schematic of the RA signaling pathway, which plays a key role in 
embryogenesis and adult tissue homeostasis. The cell surface protein STRA6 accepts all-trans retinol from 
the extracellular milieu to transfer it across the cell membrane into the cytoplasm. STRA6 does not transport 
retinoic acid. After transfer or diffusion into cytoplasm, the internalized free retinol is bound to CRBP or is 
oxidized to retinal by retinol dehydrogenases (RDH) or alcohol dehydrogenases (ADH) and eventually to form 
all-trans retinoic acid (ATRA) by aldehyde dehydrogenases (ALDHs). ATRA then binds to cellular retinoic 
acid-binding proteins (CRABPs), which transfers ATRA to the nucleus. Once localized in the nucleus, ATRA 
serves as a ligand for binding to retinoid X receptors (RXRs) and retinoic acid receptors (RARs). Once ATRA 
travels to the nucleus, it binds RARs to induce the transcription of retinoid-responsive genes. Specifically, bound 
ATRA (or other ligands such as 9-cis) induces formation of a heterodimer (RA:RAR:RXR) in a complex 
at retinoic acid receptor elements on DNA, which then is able to induce transcription of RA-response genes. 
Thus, the RAR:RXR heterodimer acts as the main transcription factor in the classical RA signaling pathway. 
Nonetheless, the rate of formation of the RA:RAR:RXR complex, is still affected by other intracellular RA 
binding proteins such as CRABPs, which can sequester RA in the cytosol and limit the amount of RA available 
for binding to RARs. CRABPs can also facilitate RA degradation by directing RA to CYP26A1 RA-degrading 
enzymes. STRA6 = stimulated by retinoic acid 6, RDHs = retinol dehydrogenases, ADHs = alcohol 
dehydrogenases, RBPs = retinol binding proteins, ALDHs = aldehyde dehydrogenases, CRABPs = cellular 
retinoic acid binding proteins, CYP26A1 = cytochrome p450 family 26 subfamily a member 1, RARE = retinoic 
acid response element; RXRs = retinoid X receptors, RARs = retinoic acid receptors.
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and retinoid homeostasis. Specifically, RBP1 is the carrier protein for transport of 
retinol from the liver storage site to peripheral tissue. RBP2 also plays an important 
role in the uptake and intracellular transport of retinol, which is necessary for 
intracellular metabolism of vitamin A.
2.7 ALDHs (aldehyde dehydrogenases)
ALDHs are cytoplasmic enzymes that convert/oxidize retinaldehyde to RA. 
ALDHs are the enzymes that function after the alcohol dehydrogenase step in the 
RA signaling pathway. Nineteen ALDH isoforms encoded by 19 different genes exist 
in humans with as many orthologs in the mouse plus some alternatively spliced 
transcriptional variants. Through its role in retinol metabolism, ALDHs play a 
major role in the regulation of responses to RA.
2.8 CRABPs (cellular retinoic acid-binding proteins)
CRABP1 (Cellular Retinoic Acid Binding Protein 1) and CRABP2 (Cellular 
Retinoic Acid Binding Protein 2) are paralogous genes that encode cellular RA 
binding proteins. These proteins transport RA to the nucleus and function to 
regulate the access of RA to the nuclear RA receptors. Specifically, CRABPs are 
cytosol-to-nuclear shuttling proteins, which facilitate RA binding to its cognate 
receptor complex and nuclear transfer. These activities in the retinoid signaling 
pathway play an important role in RA-mediated differentiation and proliferation 
processes. CRABPs are structurally similar to the cellular retinol-binding proteins, 
but CRABPs only bind RA, which contributes to RA-directed differentiation in 
epithelial tissue. Diseases associated with CRABPs include embryonal carcinomas.
2.9 CYP26A1 (cytochrome P450 family 26 subfamily A member 1)
CYP26A1 is a cytochrome P450 monooxygenase that plays a key role in the 
metabolism of ATRA. The cytochrome P450 superfamily contains 57 members 
that are monooxygenase enzymes which catalyze many processes including drug 
metabolism and synthesis of cholesterol, steroids, and various lipids. CYP26A1 
acts on ATRA by catalyzing the hydroxylation of carbon hydrogen bonds of ATRA. 
This includes both 4-hydroxylation and 18-hydroxylation activities. It has little 
activity toward 9-cis and 13-cis RA ligands. By regulating intracellular concentra-
tions of RA, CYP26A1 can control RA signaling mediated gene expression in both 
embryonic and adult tissues. There are two alternatively spliced transcript variants 
of CYP26A1 that encode the different isoforms. This enzyme regulates the cellular 
level of RA which in turn regulates gene expression in both embryonic and adult 
tissues. Diseases associated with CYP26A1 include embryonal carcinoma and APL.
2.10 Retinoid X receptors (RXRs) and retinoic acid receptors (RARs)
The proteins encoded by RARs (RARA, RARB, RARG) and RXR (RXRA, RXRB, 
RXRG) genes are classified as members of the steroid and thyroid hormone receptor 
superfamily of transcriptional regulators. Various receptor isoforms can result from 
differential splicing of RA receptor genes and alternate promoter usage. RXRs and 
RARs are nuclear receptors that are central to retinoid acid (RA) signaling through 
their role in RA-mediated gene activation in response to their ligands ATRA or 9-cis 
retinoic acid. The 9-cis RA ligand has a high affinity for RXRs. These receptors are 
localized to cytoplasm and sub-nuclear compartments where they can bind RA to 
activate cellular signaling by forming homodimers or heterodimers. These dimers 
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primarily act as transcription factors via binding to the retinoic acid response ele-
ments (RARE) made of tandem 5’-AGGTCA-3′ sites known as DR1-DR5. When the 
ligand is absent, RXRA/RARB forms a multiprotein complex containing transcription 
co-repressors that can induce histone deacetylation, chromatin condensation and 
transcriptional suppression. When the ligand is present, it induces the co-repressors 
to dissociate from the receptors and co-activators are recruited which leads to tran-
scriptional activation. Moreover, depending on the RARE DNA element condition, 
the heterodimer can act as a transcriptional repressor or transcriptional activator. For 
example, the heterodimer can act as a repressor on the DR1 element and as an activa-
tor on the DR5 element. RA receptors can also dimerize with thyroid hormone, and 
vitamin D receptors, which increases their DNA binding and transcriptional effects on 
their respective response elements. RA signaling regulates gene expression in various 
biological processes such as embryonic morphogenesis, granulocytopoiesis, and 
skeletal growth. It also plays an essential role in mediating the antiproliferative effects 
of RA by inducing cellular differentiation and apoptosis. In oncology, translocations 
between RARA and other loci are associated with the development of APL.
Now that we have briefly covered the key components in the RA signaling 
pathway that are critical to its proper function, we will discuss alterations of this 
pathway that occur in CRC.
3. Studies on alterations of retinoic acid signaling in CRC
Many studies have been done to identify mechanisms that explain how RA 
resistance occurs in solid tumors. Indeed, CRCs have been shown to lose the ability 
to produce ATRA and fail to growth inhibit or differentiate in response to treatment 
with ATRA [14–16]. Retinoic acid resistance appears to arise spontaneously in human 
cancers. To assess how alterations in RA signaling components effect response to RA 
ligands, we performed a literature search. Most of the published studies discussed 
below used in vitro experiments on CRC cell lines and analysis of human CRC tissues.
In a study by Jette et al. [16], seven CRC cell lines were evaluated for retinol 
dehydrogenase (RDH) enzymatic activity. They found CRC cells have decreased 
conversion of retinol into RA compared to normal cells. This inhibition of RDH 
expression appeared to be due to loss of adenomatous polyposis coli (APC) func-
tion. Interestingly, reintroduction of wild-type APC into an APC-mutant CRC cell 
line (HT29) increased expression of DHRS9 (RDHL) but not RDH5. Transfection 
of wild-type APC also increased production of RA. This study indicates intracellular 
crosstalk occurs between WNT signaling and RA signaling pathways.
Another study by Park et al. [14] examined the ability of retinol to inhibit the 
growth of CRC cell lines. They observed that some CRC cells are ATRA-sensitive 
(HCT-15) and other cells are ATRA-resistant (HCT-116, SW620, and WiDR). They 
also found that retinol inhibited the growth of both ATRA-sensitive and ATRA-
resistant CRC cells through a RA receptor-independent mechanism.
Other studies by Shelton et al. [17] evaluated for over-expression of CYP26A1 
enzymes that could lead to increased ATRA degradation. Indeed, CYP26A1 was 
upregulated in APC–deficient CRC tissues which provides a mechanism that might 
explain how increased WNT-signaling might be tied to impaired RA-signaling func-
tion in ATRA-resistant cells.
Lecithin retinol acyltransferase (LRAT), which esterifies retinol to retinyl esters, 
has also been evaluated by Cheng et al. [18]. Indeed, the LRAT gene promoter was 
hypermethylated in CRC cell lines and neoplasms compared to normal tissue [18]. 
A decrease in LRAT expression due to hypermethylation could lower availability of 
retinoids and reduce intracellular storage of retinol.
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Additionally, several studies have investigated whether RA receptors are intact 
in CRC cells [19]. We discuss below a few studies that reported loss of RAR in 
CRC cells. In one study by Moison et al. [20], epigenetic changes appeared to lead 
to loss of RARB expression in HCT116 cells from DNA hypermethylation [20]. 
Interestingly, a DNA methylation inhibitor is able to restore RARB expression [21]. 
In a second study by Nicke et al. [22], the RA-resistant LoVo CRC line was induced 
to over-express RARB, which produced responsiveness to ATRA resulting in growth 
inhibition. A third study by Lee et al. [23] had similar results. They observed that 
ATRA treatment of RA-sensitive and RA-resistant CRC lines induced RARA expres-
sion in all cell lines, but ATRA only increased RARB expression in lines that were 
sensitive to RA. The DLD-1 RA resistant cells acquired sensitivity to ATRA when 
RARB was over-expressed. Additional studies that examine RA resistance due to 
alterations in RARs have also been reported [23, 24].
Finally, a recent study by Kropotova et al. [15] used RT-PCR to measure expres-
sion patterns of genes involved in ATRA biosynthesis. They evaluated normal 
human colorectal tissues, primary carcinomas, and cancer cell lines. Expression of 
most genes involved in ATRA synthesis was altered in CRC tumors and colorectal 
cell lines. Moreover, the expression of several genes, particularly ADH isoforms 
ADH2 and ADH3, showed decreased gene expression in adenomas when compared 
to more advanced carcinomas.
Overall, the studies on CRC discussed above show that RA signaling compo-
nents become altered at many levels along the pathway. This includes: (i) loss of 
RAR expression that impairs RA response and gene transcription; (ii) decreased 
ability to enzymatically synthesize ATRA; (iii) LRAT alterations that impair 
retinoid storage; (iv) enhanced degradation of ATRA via CYP26A1. Many of these 
alterations appear to be a consequence of the mutations, such as APC, that drive 
CRC development [1, 25]. Thus, as CRC progresses, tumor cells develop resistance 
to ATRA by losing their ability to produce and respond to it, as well as, by causing 
its degradation.
4. Animal model studies
In addition to the studies on RA signaling in cell lines and CRC tissues 
discussed above, other important investigations have been done using animal 
models. Many of these studies were done using azoxymethane (AOM) or 
1,2-dimethylhydrazine (DMH) to induce colonic neoplasms in rats to investigate 
the anti-tumor effects of retinoids [26]. An early study by Stopera and Bird [27] 
found that ATRA treatment reduced the number of AOM-induced aberrant crypt 
foci (ACF), a precursor to CRCs. Two studies [28, 29] using the DMH-induced 
colon carcinogenesis model indicated that vitamin A dietary supplementation 
may diminish ACF formation. Other studies by Wargovich et al. [30, 31] reported 
that 13-cis-retinoic acid (13-cRA), 9-cis-retinoic acid, and the synthetic Vitamin 
A derivative 4-hydroxy-phenretinamide (4-HPR) diminished AOM-induced ACF 
in rats. An interesting study by Zheng et al. [32] screened thirteen retinoids for 
prevention of ACF. They found that two retinoids, 9-cis-retinoic acid and 4-HPR, 
reduced both colonic ACF and tumor formation. In another study by Zheng et al. 
[33], 2-(carboxyphenyl)retinamide (2-CPR) was evaluated because it prevents 
ACF. However, they found that this synthetic retinoid analogue increased the 
number of colon tumors. Thus, these studies on rats show that ATRA, retinol, 
9-cis-retinoic acid, 4-HPR, 13-cRA, and 2-CPR can inhibit the formation of 
carcinogen-induced ACF. However, only 9-cis-retinoic acid and 4-HPR were 
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shown to reduce colonic tumor formation, and 2-CPR actually increased the 
number of colon tumors in this rat model.
Several other animal studies to evaluate the effect of retinoids have employed 
the ApcMin/+ mouse model. Experiments using this model are important because 
these mice develop intestinal tumors due to Apc mutations and APC is a driver 
mutation for CRC growth in humans.
A study of ApcMin/+ mice by Volate et al. [34] showed that retinoic receptors 
including Rara, Rarb, Rxrb, Rxrg were all expressed in ApcMin/+ adenomas. However, 
in AOM-treated ApcMin/+ mice, Rxra was selectively downregulated in intestinal 
tumors. Therefore, these findings indicate that Rxra downregulation occurs early in 
CRC carcinogenesis and is not dependent on Apc mutations and beta-catenin.
Another study by Mollersen et al. [35] administered ATRA to ApcMin/+ mice and 
discovered that ATRA treatment failed to prevent tumor formation. Three studies 
were then performed that gave results which provide mechanisms that helps explain 
this unexpected ATRA resistance.
One line of investigation focused on C-Terminal Binding Protein 1 (CTBP1), which 
has been reported to inactivate retinoid dehydrogenase RDH [36]. Examination of 
adenomas from ApcMin/+ mice and familial adenomatous polyposis coli (FAP) patients 
showed an increased expression of CTBP1. Because CTBP1 decreases RDH levels, 
upregulated CTBP1 will lead to lower ATRA levels in tumors [37].
In another study on ApcMin/+ mice, Shelton et al. [17] analyzed expression levels 
of CYP26A1, the major RA catabolic enzyme. They found that CYP26A1 expression 
was increased in tumors from ApcMin/+ mice, and in tumors from FAP patients. They 
also determined that CYP26A1 is a TCF4 target gene which explains why CYP26A1 
expression is increased due to upregulated WNT signaling in APC mutant tissues. 
An increase in CYP26A1 would lead to increased ATRA degradation, which pro-
vides a mechanism that helps explain why ATRA treatment failed to prevent tumor 
development in ApcMin/+ mice.
A recent innovative study by Penny et al. [38] involved treating ApcMin/+ mice 
with the CYP26a inhibitor Liarozole. Administration of Liarozole to ApcMin/+ mice 
increased endogenous RA signaling (presumably by blocking ATRA metabolism) 
and effectively reduced intestinal adenoma numbers in these Apc mutant mice. We 
also found that treatment of human CRC cells with Liarozole decreased prolifera-
tion, sphere formation and size of the ALDH+ stem cell population [39]. This 
suggests that Liarozole might decrease tumor stem cell numbers in APC mutant 
tissues.
Thus, the above discussed animal model studies have provided valuable infor-
mation on how the retinoid pathway might be targeted in designing treatment 
approaches for human CRC patients. The studies using chemical carcinogen models 
show that different retinoid drugs have different activities against colon tumors. 
The studies using the ApcMin/+ model reveal it might be an effective screen for other 
retinoid drugs that have anti-tumor activity against APC mutant tissues. Perhaps a 
reasonable place to start would be to screen other agents for their ability to inhibit 
specific cellular processes upregulated in tumors that lower endogenous ATRA 
levels and decrease RA signaling.
5. Clinical studies
There have been an increasing number of clinical trials done on solid tumors 
using retinoids. However, our search of trials listed www.clinicaltrials.gov does not 
show any trials on CRCs using retinoids, Tretinoin or Liarozole. There were several 
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trials listed for breast, lung, prostate, pancreatic, renal, cervical, brain, skin, and 
several hematologic malignancies. Given the pre-clinical data discussed above, it 
seems like it would be reasonable to develop a retinoid-based trial for CRC.
6. Prospect for retinoid-based, stem cell-targeted therapies for CRC
We have been interested in the role of RA signaling in regulation of colonic 
SCs and how dysregulation of RA signaling may contribute to CRC development 
for several reasons: (i) RA regulates embryonic SCs during development [40] and 
WNT signaling, another key developmental pathway, has an opposing effect on 
embryonic SCs [41]. The idea that the mechanisms that regulate embryonic SCs are 
the same mechanisms that become dysregulated in the SC etiology of cancer [42] is 
intriguing because some scientists view cancer as aberrant organogenesis [43] and 
metastases as aberrant morphogenesis [44]. (ii) APC mutations occur in most CRCs 
(nearly 90%) during CRC development and APC mutation leads to constitutively 
activated WNT signaling. (iii) APC mutations that drive CRC development appear 
to do so by causing SC overpopulation [45]. (iv) ALDH, a key component in RA sig-
naling, marks colonic SCs and tracks SC overpopulation during CRC development.
Indeed, our research team [39, 46–49] and others [50–52] have been using 
ALDH as a marker to identify and isolate SCs from patient tissues for several years. 
ALDH not only marks colonic SCs, but ALDH+ cells also have SC properties of 
self-renewal, drug resistance, and cell differentiation potential [53]. For example, 
ALDH+ cells possess self-renewing ability as shown by sphere-forming ability 
in vitro and tumor-initiating ability in mice [46, 51, 52, 54]. The drug resistance 
property of ALDH+ SCs comes from aldehyde dehydrogenase’s enzymatic func-
tion, which is the cell’s natural detoxification mechanism [50, 55, 56]. The ability of 
ALDH+ cells to differentiate comes from ALDH’s functional role in the RA signal-
ing pathway [5, 13, 57–59]. Moreover, we examined ALDH+ cells from colon tissues 
and observed that retinoid receptors RXR and RAR are selectively expressed in 
ALDH+ cells [39], which indicates that RA signaling mainly occurs via ALDH+ SCs. 
That RA signaling primarily occurs in ALDH+ stem cells provides a mechanism for 
selective treatment of SCs using RA analogues.
ATRA is commonly used as a differentiating agent in SC research. For example, we 
found that treatment of ALDH+ cancer SCs (CSCs) with ATRA inhibits cell prolifera-
tion, reduces SC proliferation, sphere formation, and SC population size, as well as 
enhances SC differentiation [39, 47]. Others have shown that retinoids decrease pro-
liferation of ALDH+ SCs and, conversely, that inhibitors of ALDH increase prolifera-
tion of ALDH+ SCs [4, 6–8]. Because ALDH is key to retinoid acid (RA) signaling and 
retinoids are well known to promote differentiation of SCs [4], it follows that having 
ALDH in a SC provides the capacity for it to differentiate in response to retinoids.
Since APC mutations are known to increase WNT signaling in CRC, this raises 
the question: does increased WNT signaling lead to decreased retinoid signaling? 
Indeed, previous studies have implicated a role for APC in regulating RA biosyn-
thesis and that APC mutations may lead to aberrant RA signaling [16, 36]. Notably, 
studies show that appropriately regulated WNT signaling is necessary for RA to 
induce neuronal differentiation of embryonic SCs [60]. Furthermore, not only does 
WNT suppress retinoid signaling, but conversely, increased RA signaling dimin-
ishes the ability of WNT signaling to block retinoid induction of the neural dif-
ferentiation of SCs [61, 62]. That WNT signaling must be downregulated for neural 
differentiation to be inducible by RA treatment helps explain how APC mutation 
and increased WNT signaling might prevent maturation of ALDH+ colonic SCs 
in CRC development. Thus, it appears that APC mutations may alter the ability of 
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ALDH+ SCs to differentiate in response to retinoids, which would lead to expansion 
of the ALDH+ SC population size in CRC [39, 46].
7. Bioinformatics analysis of retinoid signaling components in CRC
We extended our study of RA signaling in CRC herein by using bioinformatics 
to analyze expression and mutation of RA signaling genes in CRCs and identify 
RA pathway genes that predict CRC patient survival. We found that most genes 
in the RA pathway are overexpressed and many are mutated in CRC (Figure 2). 
This is consonant with our previous result showing that RAR, RXR and other RA 
signaling proteins are overexpressed in CRC, which parallels overpopulation of 
ALDH-positive SCs that occurs during CRC tumorigenesis [39, 46]. Moreover, we 
found that aberrant expression of many RA signaling proteins (10 of 27) predicted 
(p < 0.05) decreased survival of CRC patients (Figure 3). We refer the reader to the 
meta-analysis by Chen et al. [63] which reveals that increased ALDH also indicates 
a poor prognosis in CRC patients. These updated findings provide insight into the 
complexity of RA signaling mechanisms and how RA signaling, when dysregulated, 
contributes to the development of CRC.
Figure 2. 
Bioinformatics analyses of RA signaling genes in CRC, including overexpression (a) and mutations (b). 
Bioinformatics data derived from cosmic catalog of somatic mutations in cancer (https://cancer.sanger.ac.uk/
cosmic).
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Figure 3. 
Kaplan-Meier survival analysis of RA signaling genes that predict (p < 0.05) CRC patient survival. (A) shows survival curves for RARs (retinoic acid receptors), RXRs (retinoid X receptors), 
CRABPs (cellular retinoic acid binding proteins), and RBPs (retinol binding proteins). (B) shows survival curves for LRAT (lecithin retinol acyltransferase), RDHs (retinol dehydrogenases), and 
DHRS3 (retinaldehyde reductase-3). (B) shows survival curves for CYP26A1 (cytochrome P450 family 26 subfamily A member 1), STRA6 (stimulated by retinoic acid 6), and ADHs (alcohol 
dehydrogenases). Curves reflect low (blue) and high (red) gene expression. Y axis = survival probability (0.0–1.0). X axis = time (years 0–12). Bioinformatics data derived from the human protein 
atlas (https://www.proteinatlas.org).
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CRC Cell 
line
APC 
mutation
Microsatellite 
instability
Beta-catenin 
mutation
RARA 
mutation
RARB 
mutation
RARG 
mutation
RXRA 
mutation
RXRB 
mutation
RXRG 
mutation
HT-29 Yes Stable No No No No No No No
SW480 Yes Stabe No Yes No No No No Yes
HCT116 Yes High Yes Yes No No No No No
LoVo Yes Low Yes No No No Yes No No
DiFi Yes Stabe Yes No No No No No No
SW48 Yes High Yes Yes No No No No No
SW1116 Yes Stabe No No No No Yes No No
COLO320 Yes Stabe No No No No No No No
LIM1863 Yes Stabe Yes ? ? ? ? ? ?
DLD-1 Yes Stabe No ? ? ? ? ? ?
RKO No High No No No No Yes No Yes
Analysis done using the COSMIC database on human somatic mutations in cancer (https://cancer.sanger.ac.uk/cosmic).
Table 1. 
Bioinformatics results on RXR and RAR mutations in CRC cell lines.
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8. Conclusion and future perspectives
Our results indicate that RA signaling, when dysregulated, plays a major role 
in the SC origin of CRC. Overall, our review provides a strong rationale for future 
exploration of retinoid therapies for CRC in precision oncology. A few clues gleaned 
from our review are as follows: (i) drug screens using CRC cell lines (Table 1) and 
knockout of RA-signaling genes in human CRC cells might identify which retinoid 
drugs are active against cells with specific mutations; (ii) ApcMin/+ mice may be 
useful to identify additional retinoid agents that are active against Apc mutant 
tissues; (iii) strategies for designing retinoid-based CRC therapies will likely need 
to incorporate retinoids into drug combination regimens; (4) CRCs will likely need 
to be genotyped to determine the status of RA signaling genes when administering 
RA-based treatments to CRC patients. Finally, continued discovery of the mecha-
nisms that explain how RA signaling regulate normal colon SCs and how dysregula-
tion of RA signaling in cancer SCs drive CRC growth should provide insight into 
how new SC-targeted therapies might be designed for CRC.
8.1 Materials and methods
The bioinformatics analysis on overexpression and mutation of RA signaling 
component genes in CRCs was done through the COSMIC website (cancer.sanger.
ac.uk/cosmic). Bioinformatics analysis to identify RA signaling genes that predict 
CRC patient survival was done through The Human Protein Atlas (https://www.
proteinatlas.org).
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